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Abstract
The development of targeted molecular therapies has provided remarkable advances into the treatment of human cancers.
However, in most tumors the selective pressure triggered by anticancer agents encourages cancer cells to acquire resistance
mechanisms. The generation of new rationally designed targeting agents acting on the oncogenic path(s) at multiple levels
is a promising approach for molecular therapies. 2-phenylimidazo[2,1-b]benzothiazole derivatives have been highlighted for
their properties of targeting oncogenic Met receptor tyrosine kinase (RTK) signaling. In this study, we evaluated the
mechanism of action of one of the most active imidazo[2,1-b]benzothiazol-2-ylphenyl moiety-based agents, Triflorcas, on
a panel of cancer cells with distinct features. We show that Triflorcas impairs in vitro and in vivo tumorigenesis of cancer
cells carrying Met mutations. Moreover, Triflorcas hampers survival and anchorage-independent growth of cancer cells
characterized by ‘‘RTK swapping’’ by interfering with PDGFRb phosphorylation. A restrained effect of Triflorcas on metabolic
genes correlates with the absence of major side effects in vivo. Mechanistically, in addition to targeting Met, Triflorcas alters
phosphorylation levels of the PI3K-Akt pathway, mediating oncogenic dependency to Met, in addition to Retinoblastoma
and nucleophosmin/B23, resulting in altered cell cycle progression and mitotic failure. Our findings show how the unusual
binding plasticity of the Met active site towards structurally different inhibitors can be exploited to generate drugs able to
target Met oncogenic dependency at distinct levels. Moreover, the disease-oriented NCI Anticancer Drug Screen revealed
that Triflorcas elicits a unique profile of growth inhibitory-responses on cancer cell lines, indicating a novel mechanism of
drug action. The anti-tumor activity elicited by 2-phenylimidazo[2,1-b]benzothiazole derivatives through combined
inhibition of distinct effectors in cancer cells reveal them to be promising anticancer agents for further investigation.
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Introduction
Receptor tyrosine kinase (RTK) signaling has been implicated
in tumor evolution for its capacity to influence cell fate through
changes in key regulatory circuits [1–3]. As evidenced by cancer
genomic studies, RTK signaling is one core pathway frequently
altered in human cancer [4,5]. We have recently shown the
relevance of signaling nodes interconnecting RTK and p53 core
pathways and the impact of targeting such nodes during tumor
evolution [6,7]. The relevance of altered RTKs in oncogenesis has
drawn tremendous interest to identify agents capable of restraining
their activity and function. To date, molecular therapies for
‘‘RTK-addicted’’ cancer cells are mainly based on the application
of compounds that selectively target the oncogenic RTK [1].
However, the success of these strategies has been limited since
inhibition of the ‘‘primary RTK-addiction’’ triggers a selective
pressure on cancer cells to acquire resistance through ‘‘RTK
swapping’’ [8,9]. These limitations impose the identification, or
the combined use, of agents that not only target RTK signaling
dependency, but also hamper adaptation caused by redundancy in
the RTK signaling network [10].
One approach to circumvent ‘‘RTK swapping’’ could be the
identification of drugs interfering with oncogene dependency by
acting at multiple levels within the addiction path. An example of
this concept is provided by Sorafenib, a small chemical agent able
to inhibit several RTKs, including VEGFR, PDGFRb, Kit,
FGFR1, Ret, and the intracellular Raf kinase [11]. The broad-
spectrum activity of Sorafenib in several cancer models is likely
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due to the wide range of its targets. Nevertheless, Sorafenib activity
in some types of tumor models is attributed to the concomitant
inhibition of RTK-driven angiogenesis and the RTK downstream
Raf/MAPK pathway [11]. The generation of agents, which target
oncogenic path(s) at multiple levels, is not a simple issue as distinct
targets require a precise drug structure and chemical modifications
of drugs can either affect selectivity (e.g. by targeting multiple
RTKs), effectiveness, or toxcicity. In contrast to other RTKs, the
hepatocyte growth factor (HGF) receptor Met is characterized by
unusual structural plasticity as its active site can adopt distinct
inhibitor binding modes [12]. Indeed, a wide range of small-
molecules have been discovered as Met inhibitors [13,14].
Nevertheless, efforts continue to uncover novel anti-Met agents
for targeted therapies and associated resistance mechanisms [8,15–
17].
To identify chemical agents capable of inhibiting oncogenic Met
signaling in cancer cells, we previously applied a Met-focused cell-
based screen. We had reasoned that such a strategy would offer the
possibility of identifying compounds that may: a) elicit inhibitory
effects directly on Met; b) target other essential components in the
Met signaling cascade; c) be well tolerated due to limited toxic
effects at biologically active concentrations [18–20]. We reported
that new amino acid amides containing the imidazo[2,1-
b]benzothiazol-2-ylphenyl moiety target Met directly and inhibit
oncogenic Met function, without eliciting major side effects in vitro
[19]. In this study, we explored the anticancer activity of one of the
most active agents we have identified, Triflorcas (TFC), on a panel
of cancer cells with distinct characteristics and investigated its
mechanism of drug action by a range of complementary
approaches. We show that Triflorcas targets cancer cells either
carrying Met mutations or characterized by RTK swapping. We
demonstrate that Triflorcas is well tolerated in vivo and does not
significantly alter the expression of several cell toxicity and stress
genes. Biochemical and phospho-screening array studies revealed
that Triflorcas predominantly alters the phosphorylation levels of
the PI3K/Akt pathway, which ensures oncogenic dependency to
Met, as well as Retinoblastoma (Rb), and nucleophosmin/B23.
These alterations functionally correlate with changes in cell cycle
progression underlying mitotic failure. Although Triflorcas anti-
cancer activity correlates with its inhibitory effects on Met, its drug
action mechanisms may not be merely restricted to Met target
itself. The unique ability of Triflorcas to modulate multiple
pathways deregulated in tumor cells with aberrant Met signaling
further strengthens the prospect of exploiting the flexible-binding
mode capacity of Met active site to identify new agents with
inhibitory properties towards signaling targets required to execute
the oncogenic program. Finally, the assessment of the inhibitory-
response profile on cancer cells through the National Cancer
Institute anticancer drug screen suggests that Triflorcas is
characterized by a novel mechanism of drug action. Bioinfor-
matics studies indicate possible molecular signatures that correlate
with cancer sensitivity to imidazo[2,1-b]benzothiazol-2-ylphenyl
moiety-based agents.
Results
Triflorcas Inhibits Survival and Anchorage-independent
Growth of Human Cancer Cells Carrying Mutated Met
We first examined the effect of Triflorcas on two human non-
small-cell lung cancer (NSCLC) cells carrying Met mutations:
H2122 and H1437 cells, harboring point mutations at the amino
acid residue N375S and R988C, respectively [21]. Triflorcas
impaired survival and anchorage independent growth of H2122
and H1437, respectively (Figure 1A and B). None of the Met
inhibitors used as reference compounds, such as SU11274,
crizotinib, and PHA665752 interfered with survival and in vitro
tumorigenesis of these cells (Figure 1A and B). In contrast, all
tested inhibitors impaired survival and anchorage independent
growth of human gastric carcinoma GTL-16 characterized by Met
amplification (Figure 1A and B), as previously reported [19,21].
These data suggest that Triflorcas exerts a marked inhibitory effect
on cancer cells with Met mutations, which are not sensitive to
other Met inhibitors, in addition to cells carrying Met amplifica-
tion.
Triflorcas Interferes with Met Phosphorylation, with Met
Localization, and with PI3K-Akt Pathway Activation
We have previously shown that Triflorcas interferes with Met
phosphorylation in living cells and with Met activation in vitro
[19]. We therefore investigated the effects of Triflorcas on Met in
H1437 cells by following Met phosphorylation on two tyrosine
residues located in its kinase domain, Tyr1234 and Tyr1235.
Immunocytochemical analysis revealed Met phosphorylation
predominantly on the plasma membrane when H1437 cells were
exposed to HGF stimulation (Figure 2A). Notably, we found that
Triflorcas leads to changes in phosphorylated Met: a) down-
regulation of its phosphorylation levels and b) a predominant
localization in intracellular compartments (Figure 2A). Treatment
with chlorpromazine, a cationic amphipathic drug that inhibits
clathrin-mediated endocytosis, restored phospho-Met localization
at the cellular membrane, thus indicating that Triflorcas enhances
Met internalization (Figure 2A) Reduced Met phosphorylation was
also observed in protein lysates from H1437 cells accompanied by
reduced Met protein levels (Figure 2B). Densitometric analysis
indicated that Met down-regulation through endocytosis causes
the decrease in Met phosphorylation (data not shown). Consis-
tently, we found reduced phosphorylation of Gab1, which is an
immediate signaling target of Met (Figure 2B).
The biological effect of Triflorcas on cells carrying Met
mutations and Met amplification (Figure 1) [19] led us to evaluate
the phosphorylation status of RTK downstream effectors. Among
pathways required in cancer cells with oncogenic Met, it has been
shown that only a subset of Met-activated pathways sustains the
dependency of cancer cells on Met. In particular, the Ras/ERKs
and the PI3K/Akt are two pathways that predominantly ensure
dependence on oncogenic Met [22]. We therefore explored
whether Triflorcas restricts the activation of these two pathways by
following the phosphorylation level of ERKs and Akt in H1437
cells. No significant changes were observed on HGF-induced ERK
phosphorylation when H1437 cells were exposed to Triflorcas
(Figure 2B). In contrast, Akt phosphorylation was significantly
reduced after Triflorcas treatment (Figure 2B). Reduced phospho-
Akt was paralleled with a decrease in the phosphorylation levels of
its downstream signal p70S6K (Figure 2B). Consistently, reduced
phosphorylation levels of Akt and its downstream signals p70S6K
and S6 ribosomal protein, but not ERKs, were observed also in
GTL-16 cells (Figure 2C). We confirmed the functional relevance
of intact PI3K/Akt signaling for anchorage-independent growth of
H1437 and GTL-16 cells by pharmacologically blocking its
activation with LY294002 (PI3K inhibitor) or A-443654 (Akt
inhibitor) (Figure 2D, E, S1A, and 1B). The decrease of Akt
phosphorylation after Triflorcas treatment was also observed in
the ErbB1-addicted human breast cancer BT474 cells, where
ErbB1 phosphorylation levels were unchanged (Figure S1C) [19].
Together, these results indicate that the reduction of PI3K/Akt
pathway activation by Triflorcas is not merely a consequence of
the inhibition of upstream RTK activity. We also found that Akt
activity is not required for survival of BT474 cells (Figure S1D).
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These results provide insights into BT474 cell resistance to
Triflorcas treatment by showing that their addiction to oncogenic
ErbB1 is ensured by pathway(s) other than PI3K/Akt. Together,
these findings reveal that the anti-tumor activity elicited by
Triflorcas occurs through combined outcomes on distinct effectors
involved in RTK-driven oncogenic dependency.
Triflorcas Impairs in vivo Tumor Growth of Human Cancer
Cells Carrying Met Mutation, Without Causing Major Side
Effects
We have recently reported that Triflorcas is well tolerated by
primary neurons and hepatocytes [19]. To evaluate further the
potential therapeutic application of this compound, we assessed
whether it is also well tolerated after in vivo administration.
Triflorcas was intra-peritoneally injected into mice at a dose of
30 mg.kg-1 each day. As body weight is a generic indicator of
animal physiology influenced, for example, by metabolism, animal
activity, and feeding behavior, the weight of Triflorcas-treated
mice was followed over time. No significant differences were found
versus controls and throughout treatment (P.0.05; Figure 3A).
We also measured the weight of the heart, spleen, kidney, and liver
of mice treated for 21 days and no differences were found between
the two groups (P.0.05; Figure 3B).
We previously showed that Triflorcas elicits tumor growth
inhibition of GTL-16 cells in vivo (Figure S2) [19]. We therefore
determined whether the antitumor action of Triflorcas observed in
vitro on H1437 cells might also be evidenced in vivo using
xenografted nude mice. H1437 cells (56106) were sub-cutaneously
injected into nude mice. After tumor formation, the mice were
treated with Triflorcas, crizotinib, or vehicle alone, and tumor
growth was examined during and after treatment. Notably, we
found a 58.7% and 59% reduction in tumor volume when
Triflorcas was administered at a dose of 30 mg.kg21 or
60 mg.kg21 every other day, respectively (control:
82.4 mm3678.2; 30 mg.kg21 Triflorcas injection: 34.0624.5;
P=0.04; 60 mg.kg21 Triflorcas injection: 33.8624.2; P=0.04;
Figure 3C). A reduction of tumor weight was also observed in
Triflorcas-treated mice (control: 147.1 mg 692.5; 30 mg.kg21
Figure 1. Triflorcas blocks Met-triggered cell survival and in vitro tumorigenesis of human NSCLC cells carrying Met mutations
(H2212 and H1437) and of human gastric carcinoma cells carrying Met amplification (GTL-16). (A) Survival of H2122 and GTL-16 cells was
reduced by Triflorcas at indicated concentration (mM; n= 3). In contrast, SU11274 (SU), crizotinib (crizo), and PHA665752 (PHA) impaired survival of
GTL-16, but not of H2212 cells. Cells were serum-starved for 24 hours and then incubated with compounds for 48 hours. (B) Triflorcas blocked
anchorage-independent growth of H1437 and GTL-16 cells in a dose dependent manner (n = 3). SU11274, crizotinib, and PHA665752 impaired in vitro
tumorigenesis of GTL-16, but not of H1437 cells. Values are expressed as means 6 s.e.m. **P,0.01; ***P,0.001; Student-t test.
doi:10.1371/journal.pone.0046738.g001
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Triflorcas injection: 79.1658.1, P=0.03; 60 mg.kg21 Triflorcas
injection: 62.0638.9, P=0.01; Figure 3D). In contrast, no
reduction in tumor growth was found in mice treated with
crizotinib at doses of 50 mg.kg21 every day (tumor volume:
118.6 mm3669.4; tumor size: 205.0 mg 684.8; Figure 3C and
D), consistent with previous studies [21]. Taken together, these
findings demonstrate that in vivo Triflorcas elicits tumor growth
inhibition of cancer cells with oncogenic Met. Moreover, the
absence of side effects indicates that Triflorcas is well tolerated
when injected into mice at doses required to elicit its anti-tumor
effects.
Figure 2. Triflorcas interferes with Met phosphorylation, its cellular localization, and activation of the PI3K/Akt pathway. (A) Met
phosphorylation was analyzed by immuno-cytochemistry on H1437 cells untreated, treated with HGF, with Triflorcas (TFC; 10 mM for 24 hours) or
with Triflorcas (10 mM for 24 hours) plus chlorpromazine (Chlor; 10 mg/ml for 2 hours) followed by HGF stimulation (20 ng/ml for 30 minutes).
Triflorcas reduced the levels of Met phosphorylation induced by HGF. Note also that HGF-induced phospho-Met is localized at the plasma membrane
of control cells, whereas it appears internalized in cells exposed to Triflorcas. Endocytosis inhibition with the chlorpromazine drug restored phospho-
Met localization at the cellular membrane. Arrows indicate cluster of phosphorylated Met at the plasma membrane (40X magnification). (B) HGF-
induced (20 ng/ml) phosphorylation levels of Met, Gab1, Akt, and p70S6K were reduced in H1437 cells exposed to Triflorcas. In contrast, no changes
were observed on ERKs phosphorylation levels. Similar expression levels of total Gab1, Akt, and p70S6K were also found, indicating that Triflorcas
interfered with their phosphorylation rather than with their expression levels. Western blot analyses were performed on total protein lysates. (C)
Phosphorylation levels of Akt, p70S6K, and S6 ribosomal protein, but not ERKs, were reduced in GTL-16 cells exposed to Triflorcas. Actin or Tubulin
protein levels were used as loading controls in all experiments (lower panels in B and C). (D and E) Anchorage-independent growth of H1437 (D) and
of GTL-16 (E) cells was impaired in the presence of Triflorcas (TFC), LY294002 (PI3K inhibitor), or A443654 (Akt inhibitor). Values are expressed as
means 6 s.e.m. **P,0.01; ***P,0.001; Student-t test.
doi:10.1371/journal.pone.0046738.g002
Figure 3. Triflorcas impairs in vivo tumor growth of cancer cells carrying oncogenic Met, without causing major side effects. (A)
Evolution of the body weight in mice, treated intra-peritoneally with either vehicle or Triflorcas (TFC; 30 mg.kg21 every day) showed no significant
differences. Body weight is expressed as weight evolution over the 21 day-treatment period. (B) The weight of heart, spleen, kidney, and liver was
evaluated in mice daily injected with Triflorcas (30 mg.kg21) or vehicle for 21 days. No significant differences were observed. Values are expressed as
means 6 s.e.m. P.0.05. (C and D) Triflorcas treatment (i.p. 30 and 60 mg.kg21 every other day) reduced tumor volume (C) and weight (D) in nude
mice injected sub-cutaneously with H1437 cells. Crizotinib (50 mg.kg21 daily) did not impair tumor growth. Values are reported as boxplots and
expressed as means 6 s.e.m. *P,0.05; Student-t test.
doi:10.1371/journal.pone.0046738.g003
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Minor Changes in Gene Expression Profile of Stress and
Toxicity Pathways by Triflorcas Correlate with Lack of
Toxic Effects in vivo
As Triflorcas is well tolerated both in vitro [19] and in vivo
(Figure 3A and B), we next followed gene expression levels of
a human RT-PCR array focused on toxicity and stress pathways.
The expression profile of 84 genes related to cell stress and toxicity
was analyzed in GTL-16 cells exposed to Triflorcas, SU11274, or
vehicle. SU11274 altered the expression of 39 genes for at least 2-
fold (by increasing or decreasing them; P,0.05). These genes
belong to the apoptosis/necrosis (n = 10), inflammation (n = 7),
oxidative/metabolic stress (n = 7), heat shock (n = 6), proliferation/
carcinogenesis (n = 5), and growth arrest/senescence pathways
(n = 4; Figure 4A and Table S1). In contrast, Triflorcas led to
a statistically significant change in expression of only 14 genes
(P,0.05). Among them, 13 genes overlapped with those altered by
SU11274, and belonged to apoptosis/necrosis (n = 3), oxidative/
metabolic stress (n = 3), and growth arrest/senescence (n = 3;
Figure 4A and Table S1). No significant decrease of gene
expression beyond 50% compared to control cells could be
observed. Genes showing over a 2-fold increase in expression levels
included tnf (3.83-fold; P=0.0008), gdf15 (3.18-fold; P=0.0007),
egr1 (2.68-fold; P=0.003), and serpine1 (2.42-fold; P=0.005).
Intriguingly, Triflorcas led to a robust and predominant up-
regulation of the cytochrome oxidase cyp1a1 gene (611-fold;
P=0.0001; Figure 4A). Expression of the cyp1a1 gene was also
increased by SU11274, but at significant lower levels (22-fold;
P=0.02; Figure 4A). CYP1A1 is a member of the CYP1 family of
cytochrome P450 implicated in cancer cell response to therapeutic
agents. Western blot analysis confirmed the up-regulation of
CYP1A1 protein by Triflorcas, which was impaired by its inhibitor
acacetin (Figure 4B) [23]. CYP1A1 up-regulation by Triflorcas
was independent of its action on Met as found also in cells, such as
in the human breast cancer BT474 cells (Figure 4C), which are
addicted to ErbB1 signaling. Together, these studies underline
a selective metabolism activity profile elicited by Triflorcas linked
to the up-regulation of a small subset of stress and toxicity genes.
Thus, the minimal number of genes affected by Triflorcas
indicates that this compound elicits more selective action on stress
and toxicity genes compared to other Met anticancer agents such
as SU11274.
Triflorcas Mechanisms of Drug Action and its Effects on
Cell Cycle Progression Leading to Mitotic Failure
The effects of Triflorcas on the PI3K-Akt pathway evidenced by
biochemical studies (Figure 2B and C) suggest that Triflorcas
anticancer properties may be associated with its activity on distinct
signaling targets in addition to Met. One screening approach
broadly used to identify targets of a given chemical agent is the
KINOMEscan, which allows assessing the activity of compounds
against a panel of kinases through binding assays [24]. Triflorcas
was screened against 98 kinases at a single concentration of
10 mM, in agreement with standard protocols. However, the low
solubility of Triflorcas in buffer conditions used for this type of
screen limited the possibility of identifying targeted kinases.
Nevertheless, we found that Triflorcas reduces by more than
30% the binding constant of only 5 over 98 kinases analyzed: Abl-
1 (either wild-type, or E255K and T315I mutant forms), IKK-
beta, JAK2, MKNK1, and ZAP70 (Figure 5 and Table S2).
Although the pattern of kinases interacting with Triflorcas appears
highly focused, these results must take into account that a pro-
portion of targets were possibly not detected due to the low
solubility of Triflorcas in buffer conditions used for this screen. For
example, Met was not identified despite the fact that Triflorcas
inhibitory activity was previously established using the Kinexus
compound profiling service [19].
Therefore, to further investigate the mechanism of drug action
of Triflorcas, we applied a cell-based assay, which allows
evaluation of the agent’s effects on multiple oncogenic signaling
pathways in culture conditions compatible with Triflorcas
solubility and biological activity. The phosphorylation levels of
several signaling molecules were therefore examined by using the
Kinexus phosphorylated protein screen array. In particular, we
compared the phosphorylation levels of 44 signaling phospho-
epitopes in GTL-16 cells treated or not with Triflorcas (Figure 6,
S3, and Table S3). Consistent with our biochemical studies, we
found that the phosphorylation state of several components within
the PI3K/Akt pathway was altered in cells exposed to Triflorcas.
In particular, reduced phosphorylation levels were observed for
Akt1, mTOR/FRAP, p70S6Kb1, and S6 ribosomal protein
(Figure 6A and B; red circles). Intriguingly, we found that
Triflorcas significantly alters the phosphorylation status of two
additional proteins: the phosphorylation of Rb on different Ser/
Thr residues was reduced (Figure 6A and B; blue circles); the
phosphorylation of nucleophosmin/B23, a nucleolar protein found
to be significantly abundant in tumors [25], was increased
(Figure 6A and B; green circles). Western blot analysis confirmed
changes in the phosphorylation state of Rb and nucleophosmin/
B23 proteins after Triflorcas treatment (Figure 6C).
As both Rb and nucleophosmin/B23 are key regulators of cell
cycle progression, we next evaluated whether these changes in
phosphorylation state were paralleled with alteration of the cell
cycle. Cells were stained with propidium iodide and their
distribution in different cell cycle phases was assessed by flow
cytometric analysis. Untreated GTL-16 cells were proliferating, as
confirmed by the flow cytometry pattern (Figure 7A and data not
shown). Triflorcas treatment alters GTL-16 cell cycle distribution,
with an increase of the G0/G1 cell population at the expense of
the S and G2/M population (Figure 7A and data not shown). As
controls, treatment of GTL-16 cells with either SU11274 or
nocodazol led to a blockage into G0/G1 or G2/M phase,
respectively (data not shown). Thus, Triflorcas affects cell cycle
progression of GTL-16 cells. Morphological analysis of cells
exposed to Triflorcas showed a significant increase in the number
of multinucleated cells, which indicates mitotic failure (Figure 7B
and C). In contrast, no mitotic failure was observed in cells treated
with SU11274, crizotinib, or PHA665752 (Figure 7C). Together,
these findings show that the anti-tumor activity elicited by
Triflorcas may in part account for phosphorylation changes of
distinct signaling targets, such as components of the PI3K/Akt
pathway, Rb, and nucleophosmin/B23, which correlates with
alterations in cell cycle progression and mitotic failure.
Triflorcas Impairs Survival and Anchorage-independent
Growth of Human Cancer Cells Characterized by RTK
Swapping
One major limitation of molecular therapies using agents
targeting distinct RTKs is the drug resistance mechanism, which
can be either constitutive or acquired after treatment. In this
context, it has been shown that Met, ErbBs, and PDGFRs can
reciprocally substitute for each other to maintain the activity of
RTK-driven oncogenic pathways [9,26–29]. We therefore evalu-
ated the inhibitory properties of Triflorcas in cancer cell lines, in
which reciprocal substitution of Met, ErbBs, and PDGFRb confers
resistance to single RTK inhibition. Human glioblastoma-astro-
cytoma U87 cells were used as a model of RTK swapping [27].
Survival and anchorage-independent growth assays were per-
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formed by comparing the effectiveness of Triflorcas to that of
other Met inhibitors. We found that Triflorcas impaired U87 cell
survival in a dose-dependent manner compared to SU11274,
crizotinib, and PHA665752 (Figure 8A). Notably, Triflorcas
drastically reduced anchorage-independent growth of U87 cells,
whereas both SU11274 and Gefitinib (ErbB1 inhibitor) elicited
only moderate anchorage-independent growth inhibition
(Figure 8B and C), as previously shown [27]. By evaluating the
compound IC50, we found that the Triflorcas inhibitory effects
were elicited at lower doses compared to those required in GTL-
16 Met-addicted cells (U87:0.2 mM; GTL-16:0.811 mM), and
more effectively than those elicited by SU11274 or Gefitinib
(1.9 mM and 9.5 mM, respectively; Figure 8C).
We therefore investigated whether Triflorcas acts also on other
target(s) than Met. ErbB1 and PDGFRb were two obvious
candidates as they are responsible for RTK swapping. We
excluded that Triflorcas acts on ErbB1 as: a) ErbB1 phosphory-
lation was unaffected by Triflorcas in BT474 cells (Figure S1C)
[19], and b) ErbB1 is not predominantly phosphorylated in U87
cells under normal conditions (data not shown), as previously
reported [27]. In contrast, we observed a drastic reduction in
PDGFRb phosphorylation when cells were exposed to Triflorcas
(Figure 8D). Remarkably, Triflorcas efficiently reduced PDGFRb
phosphorylation at lower doses compared to Imatinib or Nilotinib
(Figure 8D), two agents targeting PDGFRb, c-Kit, and c-Abl [30].
Triflorcas almost abolished PDGFRb phosphorylation in U87
cells at 0.3 mM, whereas Imatinib or Nilotinib partially reduced
PDGFRb phosphorylation only at 3 mM (Figure 8D). Together,
these findings show that Triflorcas exerts its anti-tumorigenic
activity also on cancer cells with oncogenic RTK swapping.
Triflorcas Elicits a Distinct Growth Inhibitory-response
Profile in Cancer Cell Lines
To further elucidate the anticancer properties of imidazo[2,1-
b]benzothiazol-2-ylphenyl moiety-based agents, we evaluated
Triflorcas bioactivity by applying the disease-oriented NCI
Anticancer Drug Screen [31]. This developmental therapeutic
program historically allowed the efficient capture of compounds
with anti-proliferative activity. In a preliminary test, Triflorcas was
assayed at a single concentration of 10 mM in the full NCI60
cancer cell line panel (Figure S4). As it satisfied predetermined
threshold inhibition criteria established for the NCI Anticancer
Drug Screen, according to a minimum number of targeted cell
lines, Triflorcas anticancer activity was then evaluated by using
a full range of concentrations, in agreement with standard
protocols (10, 100 nM, 1, 10, 100 mM). Results were expressed
as the percentage of living cells following 48 hours of incubation
(Figure 9). A decrease in cell number was seen in a proportion of
cancer cells, with the mean log10 GI50 (growth inhibition) of –
5.560.5M (Figure S5). The mean log10 LC50 (lethal concentration)
calculated for these cell lines was –4.360.3M (Figure S5).
The COMPARE algorithm allows the identification of
compounds whose pattern of growth inhibition is similar to the
agent of interest [31]. Using this approach, we found that the
Triflorcas activity correlated only minimally with that of known
standard chemotherapeutic drugs (maximal correlation 0.335;
Table S4). We further widened the comparison to the publicly
available data from synthetic compounds screened on the NCI60
cancer cell line panel, and found that none of these compounds
significantly matched with Triflorcas, as maximal correlation
reached only 0.63 (Table S5). Thus, the unique growth inhibitory-
response profile on cancer cells corresponding to solid tumors and
leukemia indicates that imidazo[2,1-b]benzothiazol-2-ylphenyl
moiety-based agents are characterized by a novel mechanism of
drug action.
To get insights into potential molecular signatures characteriz-
ing cancer cells sensitive to Triflorcas, we performed bioinfor-
matics studies using a large set of signaling database. In particular,
we compared the response of the NCI60 cancer cell line panel to
Triflorcas with NCI data resources from three databases:
‘‘Microarrays’’, ‘‘All NCI dataset’’, and ‘‘Only Protein subset
NCI’’ (Figure 10). These studies highlighted a significant corre-
lation between Triflorcas responsiveness and specific molecular
changes (belonging to strong positive and weak positive correlation
values). Signals with high correlation score included: cytoskeleton-
associated protein4 (CKAP4), secernin1 (SCRN1), mitogen-
activated protein kinase kinase 2 (MAP2K2), myristoylated
alanine-rich protein kinase C substrate (MAPCKS), SMAD4,
FIP1L1, p53, insulin-like growth factor binding protein 2
(IGFBP2), forkhead box O3 (FOXO3), and tuberous sclerosis 2
(TSC2) (Figure 11A). Notably, FOXO3 and TSC2 are known to
be regulated by the PI3K/Akt pathway, which is targeted by
Triflorcas (Figure 2 and 6). To further support bioinformatics
outcomes, we experimentally assessed Triflorcas effects on signals
highlighted in the three lists: ‘‘microarrays’’, ‘‘all NCI dataset’’,
and ‘‘only protein subset NCI’’. For this purpose, GTL-16 cells
were transfected with luciferase reporter plasmids that enable
measuring the activity of p53, Smad2/3/4, AP-1 (as read of the
MAP2K2-JNK pathway) or NFAT (as readout of the PKC-
MARCKS pathway) promoters. As Triflorcas does not affect ERK
signaling (Figure 2B and C), an Elk1-SRF reporter plasmid was
used as negative control. Luciferase activity was measured in cells
after 48 hours treatment with vehicle or Triflorcas. Consistently
with bioinformatics studies, we found that Triflorcas enhanced
luciferase activity controlled by p53, Smad2/3/4, AP-1, NFAT,
but not Elk1-SRF, promoters (Figure 11B). As JNK/AP-1 pathway
activation can lead to distinct biological outcomes ranging from
apoptosis induction to enhanced survival, tumor progression, and
metastasis, according to its strength of stimulation and the
signaling context [32], it will be relevant to assess JNK-AP-1
function on a panel of cancer cells sensitive to Triflorcas.
Together, these studies show that compounds characterized by
the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety define a new
class of chemical agents displaying anticancer activity towards
distinct cancer cell types, according to molecular signatures
indicated by bioinformatics studies.
Figure 4. Triflorcas elicits a selective gene expression profile on stress and toxicity pathways. (A) The expression profile of 84 genes
related to cell stress and toxicity was analyzed in GTL-16 cells. Cells were treated with either Triflorcas (black columns; 3 mM) or SU11274 (grey
columns; 1 mM) for 24 hours, and gene expression was compared to that of untreated cells. Genes were grouped in clusters corresponding to
oxidative/metabolic stress, heat shock, proliferation/carcinogenesis, growth arrest/senescence, inflammation, and apoptosis/necrosis signaling. Only
statistically significant changes in gene expression are indicated (P,0.05). Triflorcas altered the expression of only 14 genes compared to the
alteration of 39 genes induced by SU11274 treatment. Notably, the expression of cyp1A1 was increased 611-fold in the presence of Triflorcas. (B)
Western blot analysis showing the up-regulation of CYP1A1 protein levels in cells exposed to Triflorcas (3 or 10 mM). Acacetin (ACA; 10 mM) treatment
prevented CYP1A1 up-regulation by Triflorcas (TFC). (C) CYP1A1 up-regulation by Triflorcas also occurred in ErbB1-addicted cancer BT474 cells.
Gefitinib (Gef; 10 mM) and SU11274 (SU; 2 mM) were used as controls.
doi:10.1371/journal.pone.0046738.g004
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Discussion
Aberrant Met signaling in tumors recapitulates all the biological
events controlled by Met during embryogenesis [33–42] and
regenerative processes [43,44]. To target oncogenic Met signaling,
we originally generated a virtual chemical library of known
anticancer agents and assessed their ability to interact with Met
active site through computer modeling studies [12]. We reasoned
that the flexibility of Met active site may offer the benefit of
generating compounds in which anticancer properties and Met
inhibitory features can be merged. The previously described
imidazo[2,1-b]benzothiazol-2-ylphenyl compounds interact with
Met active sites, as evaluated by in silico studies, interfere with Met
phosphorylation, as assessed through biochemical and in vitro
kinase assays, and hamper survival and anchorage-independent
growth of Met-dependent cancer cells [19]. In the present study,
we assessed the anticancer properties of Triflorcas, one of the most
biologically active agents containing the imidazo[2,1-b]benzothia-
zol-2-ylphenyl moiety, on a panel of cancer cells. Our findings
suggest that Triflorcas and its derivatives are promising agents to
further exploit for targeting cancer cells: a) carrying Met
amplification (such as GTL-16 cells, as previously shown [19]);
b) carrying Met mutations (such as H2122 and H1437 cells); c)
characterized by RTK swapping (such as U87 cells). By
investigating the mechanism of drug action, we found that
extinction of Met oncogenic signaling by Triflorcas occurs through
at least three distinct mechanisms: a) by restraining Met activity
[19], its phosphorylation, and phosphorylation of its immediate
downstream signals such as Gab1; b) by enhancing Met
internalization and degradation; c) by decreasing the phosphor-
ylation levels of Akt and of its downstream targets mTOR, p70S6K,
and S6 ribosomal protein, one pathway known to ensure Met
dependency of cancer cells [22]. It is possibly the combination of
these three actions that allows Triflorcas to be an effective
inhibitor of cancer cells with oncogenic Met. Recent studies have
highlighted the importance of intracellular trafficking to the
cellular response of activated Met in tumorigenesis [45,46]. As
Triflorcas enhances Met internalization and degradation, it will be
relevant to assess its properties on cancer cells carrying oncogenic
forms of Met that render the receptor refractory to degradation
[46]. We also show that the inhibitory properties of Triflorcas in
cancer cells with RTK swapping can be partially attributed to its
capacity to interfere with PDGFRb phosphorylation.
Concerning the PI3K/Akt pathway, it is tempting to speculate
that Triflorcas reduces its activation to a threshold level that
becomes non-permissive for cancer cells when combined with
inhibition of other oncogenic signals. Importantly, the reduction of
PI3K/Akt pathway activation by Triflorcas, rather than its
complete inhibition with more potent and selective drugs, might
have the beneficial effect of minimizing side effects that limit the
use of these latter in clinics [47,48]. The effects on the PI3K
pathway appear to be a direct action of Triflorcas on this pathway
rather than being merely a consequence of its effects on Met.
Several data support this hypothesis: a) selective inhibition of Akt
function compromises in vitro tumorigenesis of H1437 and GTL-
16 cells; b) decreased phosphorylation levels of the Akt, but not
Ras/ERKs, pathway was observed in H1437 and GTL-16 cells; c)
reduced Akt phosphorylation was observed also in ErbB1-addicted
cells, which are resistant to Triflorcas. Beside its effects on the
PI3K/Akt pathway, Triflorcas also influences the phosphorylation
states of Rb and nucleophosmin/B23, two key regulators of cell
cycle progression. Consistently, we found that Triflorcas treatment
increases the G0/G1 cell population, leading to mitotic failure.
Future studies will clarify how Triflorcas and its derivatives
Figure 5. Small molecule kinase interaction map for Triflorcas.
Compound was screened against a KINOMEscan (http://www.
kinomescan.com) panel of 98 kinases. (A) The table indicates the
kinases for which Triflorcas reduced more than 30% the binding
constant. The ligand binding for each kinase (% of control condition) is
indicated. (B) TREEspot image of the 98 kinases screened with the
position of Triflorcas targets: Abl wild-type, Abl E255K and Abl T315I
mutant forms, IKK-beta, JAK2, MKNK1, and ZAP70. The complete
dataset is shown in Table S2. TK: tyrosine kinase; TKL: tyrosine kinase
like; STE: STE kinase; CK1: cell kinase1; AGC: PKA, PKC, PKG kinases;
CAMK: calcium calmodulin-regulated kinase; CMGC: CDK, MAP, GSK,
CDK-like kinase.
doi:10.1371/journal.pone.0046738.g005
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influence Rb and nucleophosmin/B23, whether there is a corre-
lation between changes in their phosphorylation levels and
alteration of the PI3K/Akt pathway, and whether these signaling
alterations cause microtubular network dynamic instability and
impaired mitotic spindle formation.
Our stress and toxicity RT-PCR array studies evidenced two
additional properties of 2-phenylimidazo[2,1-b]benzothiazole de-
rivatives. First, in contrast to SU11274, Triflorcas changes the
expression of only 14 out of 84 genes, which are predominantly
related to oxidative/metabolic stress, necrosis/apoptosis, and
growth arrest/senescence. This limited alteration of stress and
toxicity gene expression by Triflorcas correlates with the absence
of major side effects observed in cultured neurons and hepatocytes
[19], as well as in vivo (Figure 3A and B). Second, the expression
levels of CYP1A1 are drastically up-regulated in tumor cells
treated with Triflorcas. CYP1A1 belongs to the CYP1 cytochrome
P450 family and has been implicated in cancer cell response to
therapeutic agents by biotransforming them from prodrugs to
Figure 6. Triflorcas alters the phosphorylation status of cell cycle-related proteins. (A) The phosphorylation status of several cell cycle
proteins was analyzed by applying the phospho-array KPSS 10.1 (Kinexus Bioinformatics). GTL-16 cells were treated with vehicle (control) or Triflorcas
(TFC; 3 mM) for 72 hours (left and right panels, respectively). Red circles highlight constituents of the Akt/mTOR/S6 pathway. Green and blue circles
surround nucleophosmin/B23 and Rb phospho-epitopes, respectively. (B) The graph shows the ratio of phosphorylation levels of the indicated
proteins in cells untreated versus those exposed to Triflorcas. (C) Phosphorylation levels of nucleophosmin/B23 at Ser4 and Rb at S780 were increased
and decreased, respectively, in GTL-16 cells exposed to Triflorcas (TFC; 3 mM for 24 hours).
doi:10.1371/journal.pone.0046738.g006
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active drugs [49]. CYP1A1 is the most up-regulated gene in cancer
cells exposed to the benzothiazole derivative Phortress, its
precursor (5F-203) or its desfluoro derivative (DF-203), chemo-
therapeutic prodrugs currently evaluated in clinical trials [50]. It is
well established that these benzothiazole derivatives up-regulate,
bind covalently to, and are metabolically bioactivated by CYP1A1
Figure 7. Triflorcas perturbs cell cycle progression, leading to
mitotic failure. (A) Graph showing the ratio of percentage of GTL-16
cells in G0/G1 phase over the percentage of cells in S+G2/M phase. Cells
were treated with Triflorcas (TFC; 3 mM), or vehicle (cntr) for 48 hours,
then stained with propidium iodide. Values are expressed as means 6
s.e.m. ***P,0.001; Student-t test (n = 3). Percentages of cells in G0/G1,
S, and G2/M phases are reported in the table. (B) GTL-16 cells were
grown in the presence of Triflorcas or vehicle and nuclei were visualized
using DAPI staining. Arrows show example of cells with multiple nuclei
(40X magnification). (C) Quantification of cells with mitotic failure
expressed as percentage of the total number of cells analyzed. Triflorcas
(TFC; 3 or 10 mM), but not SU11274 (SU; 1 mM), crizotinib (crizo; 1 mM),
or PHA665752 (PHA; 1 mM) led to a significant increase in the number of
cells with mitotic failure. Values are expressed as means 6 s.e.m.
***P,0.001; Student-t test.
doi:10.1371/journal.pone.0046738.g007
Figure 8. Triflorcas impairs survival and in vitro tumorigenesis
of cancer cells resistant to single RTK inhibition through RTK
swapping by also interfering with PDGFRb phosphorylation. (A)
Survival of U87 cells was reduced by Triflorcas in a dose dependent
manner (mM; n= 2). SU11274 (SU), crizotinib (crizo), and PHA665752
(PHA) were used at the indicated concentrations (mM). (B and C)
Triflorcas (TFC) impaired anchorage-independent growth of U87 cells, in
a dose dependent manner (mM; n= 3). Gefitinib and SU11274 were used
to inhibit ErbB1 and Met, respectively. (D) PDGFRb phosphorylation in
U87 cells was drastically reduced in presence of Triflorcas. For western
blot analyses, cells were cultured in presence or absence of Triflorcas,
SU11274 (SU), Imatinib (IMA), or Nilotinib (Nilo) (0.3–3 mM). Total cell
lysates were analyzed using anti-phospho-Y751-PDGFRb (pY751-PDGFRb)
(upper panel), anti-PDGFRb (middle panel), or Tubulin (bottom panel).
Values are expressed as means6 s.e.m. **P,0.01; ***P,0.001; Student-
t test.
doi:10.1371/journal.pone.0046738.g008
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in sensitive cells [51,52]. As Phortress and Triflorcas contain
a similar heterocyclic moiety (Figure S6), it is reasonable that this
part of the molecule plays a relevant role in up-regulating
CYP1A1 expression in cancer cells. Future studies will clarify
whether CYP1A1 influences the effects of Triflorcas by generating
specific metabolites. Comparing the profiles of NCI cancer cells
responding to Triflorcas and to benzothiazole compounds [49,51],
we intriguingly found a limited overlap, indicating that Triflorcas
hampers cancer cells with mechanisms of drug sensitivity distinct
to Phortress and its derivatives. We have also evaluated the
functional relevance of CYP1A1 up-regulation by Triflorcas for its
anti-tumorigenic activity and found that CYP1A1 pharmacolog-
ical impairment did not significantly influence the inhibitory
properties of Triflorcas on cell survival and anchorage indepen-
dent growth (data not shown). Although the up-regulation of
CYP1A1 does not appear to be the main event by which Triflorcas
elicits its anti-tumor effects, we cannot exclude that, in some
neoplastic cells, the modulation of anticancer pharmaceuticals by
CYP1A1 may prove to be an advantage above additional
mechanisms of action of 2-phenylimidazo[2,1-b]benzothiazole
derivatives.
Genome-wide profiling and protein-network-based studies have
recently established two important aspects related to cancer
complexity. First, tumor evolution is often characterized by the
acquisition of mutations in a small number of ‘‘core pathways’’
[4,5]. Therefore, agents targeting a core pathway at distinct levels
could restrain its oncogenic contribution and possibly minimize
resistance mechanism. Second, RTKs share several effectors that
participate in the oncogenic process and in the drug response [9].
This opens the possibility of designing anticancer therapies
targeting mandatory signals in addition to hitting RTK activity
directly. The benefit of combining drugs acting at distinct
oncogenic levels is a well-established principle of cancer therapy,
supported by several experimental settings [10]. However, de-
termining which combinations would maximize effectiveness
among the limitless possibilities remains a major challenge. Our
studies establish that the flexibility of Met to accept different
inhibitor binding modes offers the possibility to develop drugs
targeting oncogenic Met signaling dependency at different levels as
an alternative strategy. Although these agents might be less potent
in directly impairing Met function compared to others discovered
through exhaustive co-crystallographic studies, they may offer the
possibility of lowering the activation of oncogenic dependency at
non-permissive threshold levels, minimizing redundant pathways,
either originally present in the tumor cells or acquired following
treatment. Similarly to Sorafenib and here reported outcomes for
Figure 9. Cytotoxic effects of Triflorcas on the NCI60 panel of cancer cell lines. The cytotoxic effects of Triflorcas (10, 100 nM, 1, 10,
100 mM) was determined by sulphorhodamineB assay after 48 hours of drug treatment. Results shown are representative of two independent
experiments.
doi:10.1371/journal.pone.0046738.g009
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Triflorcas, it is conceivable that compounds containing the
imidazo[2,1-b]benzothiazol-2-ylphenyl moiety may have the
ability to influence the oncogenic program by exerting modulation
of distinct targets, as also evidenced by the disease-oriented NCI
Anticancer Drug Screen. Thus, its novel mechanism of drug
action together with a favorable side effect profile makes the 2-
phenylimidazo[2,1-b]benzothiazole a relevant moiety to be further
explored for the treatment of a broad range of tumor types.
Materials and Methods
Cell Culture
Human non-small-cell lung cancer (NSCLC) H1437 and
H2122 cell lines, human breast cancer BT474 cells, and human
glioblastoma-astrocytoma U87 cells were acquired from the
America Type Culture Collection. Human gastric carcinoma
GTL-16 cells are subclones of MKN45 cells (from Riken Cell
Bank) obtained by limiting dilution [22]. H1437, H2122, BT474,
and GTL-16 cells were grown in RPMI medium (Gibco-BRL),
whereas U87 cells in Eagle’s Minimum Essential Medium
(ATCC). Culture media were supplemented with 4mM L-
glutamine and supplemented with 10% (v/v) fetal bovine serum
(Gibco-BRL), 100 U/mL penicillin, and 100 mg/mL streptomy-
cin. Cells were kept at 37uC in a humidified atmosphere of 5%
CO2. H2122 and H1437 cells were used for survival and
anchorage independent growth assays, respectively, according to
their suitability for these biological assays.
Compound Treatments
SU11274, Gefitinib, LY294002, acacetin, andresveratrol were
purchased from Calbiochem; chlorpromazine and nocodazol from
Sigma; crizotinib (PF-2341066) from Active Biochemicals;
PHA665752 from Tocris Bioscience; Imatinib and Nilotinib were
kindly provided by E. Buchdunger and P. Manley (Novartis
Pharma AG, Basel, Switzerland); A-443654 (Akt inhibitor) was
kindly provided by V.L.Giranda (ABBOTT Laboratories, Illinois,
USA). For survival assays (H2122, GTL-16, and BT474 cells) and
cell cycle analyses (GTL-16 cells), cells were cultured in serum-free
media for 24 hours prior to compound addition for 48 hours.
Survival assays with U87 cells was carried out in 0.1% serum.
Viability was assessed with the Cell-Titer-Glo-Luminescent-Assay
(Promega). For in vitro tumorigenesis, soft agar growth assays were
performed as previously described [19]. Data on biological assays
are representative of three independent experiments performed in
duplicate or triplicate.
Biochemical and Immuno-cytochemical Evaluation of
Met Inhibitors
Cells were treated with inhibitors for 24 or 72 hours, as reported
in the corresponding figures. Total extracts were analyzed as
Figure 10. Schematic representation of bioinformatic methodology applied to the NCI Anticancer Drug Screen outcomes. The
scheme displays the bioinformatics strategy applied to compare the sensitivity profile of NCI cancer cells with changes in molecular signatures from
NCI data resources. 1: Sensitiveness of NCI cell lines to Triflorcas was extracted by using the mean GI50 into a numeric format and standard scores
were visualized using green and red squares to indicate cells responding or not to Triflorcas, respectively. 2: NCI data resources applied to these
studies (whole set of 87,545 measured targets) included: ‘‘Microarrays’’, ‘‘all NCI dataset’’, and ‘‘only Protein subset NCI’’ (see Material and Methods).
The same color code was applied to indicate positive (green square) or negative (red square) changes of each molecular target analyzed.
doi:10.1371/journal.pone.0046738.g010
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described [37]. Antibodies used were anti-tubulin, anti-actin
(Sigma), anti-phosphoY1234–1235-Met, anti-p70
S6K, anti-phos-
phoT389-p70
S6K, anti-phosphoT202Y204-p70
S6K, anti-Akt, anti-
phosphoS473-Akt, anti-S6, anti-phosphoS235/236-S6, anti-phos-
phoS240/244-S6, anti phosphoT202Y204-ERKs, anti-ERKs, anti-
phosphoY627-Gab1, anti-phosphoY751-PDGFRb, anti-PDGFRb,
and anti-phosphoY1068-ErbB1 (Cell Signaling), anti-ErbBs, anti-
Met, and anti-CYP1A1 (Santa Cruz), anti-Gab1 (Upstate), Alexa
546-conjugated-goat anti-rabbit antibodies (Invitrogen).
In vivo Assays
Mice were kept at the IBDML animal facilities. All procedures
involving the use of animals were performed in accordance with
the European Community Council Directive of 24 November
1986 on the protection of animals used for experimental purposes
(86/609/EEC). The experimental protocols were carried out in
compliance with institutional Ethical Committee guidelines for
animal research (comite´ d’e´thique pour l’expe´rimentation animale
– Comite´ d’e´thique de Marseille; agreement number D13-055-21
by the Direction de´partementale des services ve´te´rinaires –
Pre´fecture des Bouches du Rhoˆne). To evaluate compound
toxicity in vivo, the weight of mice treated with Triflorcas (intra-
peritoneally (i.p.) injection: 30 mg.kg21) or vehicle was measured
before, during, and after treatment. For heart, spleen, kidney, and
liver weight, mice were sacrificed after 21 days of daily Triflorcas
or vehicle treatment. Tumor xenografts were established by sub-
cutaneous injection of H1437 cells (56106) in nude mice (S/SOPF
SWISS NU/NU; Charles River). Treatment was initiated when
tumors achieved an average volume of 15mm3 (approximately 7
days after cell injection; n= 10 mice per group). Mice were
injected with: Triflorcas (i.p. 30 or 60 mg.kg21 of body weight) or
vehicle every other day; crizotinib (oral gavage 50 mg.kg21 of
body weight, in agreement with standard protocol) daily.
Triflorcas was formulated in Cremophor-EL:DMSO (1:1, v/v)
and diluted in sterile 0.9% (w/v) sodium chloride. This
formulation is classically applied for the administration of different
chemical agents and does not elicit toxic effects, as revealed by no
changes in mouse body weight during treatment. Mice were then
sacrificed after 21 days of treatment. Tumor volume was
determined from caliper measurements of tumor length (L) and
width (W) according to the formula LW2/2. Tumor size was
measured every week and at the end of the experiment. Tumor
Figure 11. Molecular signature outcomes revealed by bioinformatic analysis of the NCI Anticancer Drug Screen. (A) Results showing
a short list of molecular targets belonging to the individual datasets and displaying high positive correlation values (on the right). (B) GTL-16 cells
were transfected with plasmids carrying the luciferase reporter gene controlled by the promoter of p53, Smad2/3/4, AP-1 (readout of the MAP2K2-
JNK pathway), NFAT (readout of the PKC-MARCKS pathway), and Elk1-SRF (readout of ERK pathway). Luciferase activity was measured in cells after 48
hours of treatment with vehicle or Triflorcas (mM). Note that Triflorcas enhanced luciferase activity controlled by p53, Smad2/3/4, AP-1, NFAT, but not
Elk1-SRF, promoters. Representative results of independent experiments are shown.
doi:10.1371/journal.pone.0046738.g011
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weight was established at the end of treatment. Two independent
assays were performed (n = 8 mice per group). For tumor
xenograft studies with GTL-16 cells, cells (106) were i.p. injected
in nude mice. Mice were treated with Triflorcas (i.p. 30 mg.kg21)
or vehicle at day 1 and treatment was repeated every other day.
Mice were then sacrificed after 21 days of treatment. Tumor
nodules present in the peritoneal cavity were isolated and
quantified according to their diameter and their total weight.
Two independent assays were performed (n= 8 mice per group).
Gene Expression Analysis
For gene expression analysis, GTL-16 cells were cultured in
serum-free media for 24 hours at approximately 40% confluence,
prior to compound addition for 24 hours (Triflorcas: 3 mM;
SU11274:1 mM). Total RNA was isolated from untreated or
treated cells using the RNAeasy-Kit, processed with DNase
(RNase-free DNase set), and purified on RNAeasy column
(Qiagen). The quality of RNA was tested by using Picochip
(Agilent Technologies). Gene profiling was done by the Super-
Array Biosciences service using the RT2-profiler PCR array Stress
and Toxicity Pathway Finder (96 genes). The data were imported
into an Excel database and analyzed using the comparative cycle
threshold method with normalization of the raw data to b-actin.
The results are presented as n-fold changes versus the values of
untreated cells. The mean value was calculated from measure-
ments of three independent biological samples.
KINOMEscan
The activity of Triflorcas was assessed on a panel of 98 kinases
through binding assays using the KINOMEscan service. The
vehicle alone was used as negative control. The KINOMEscan is
based on a competition binding assay that quantitatively measures
the ability of a compound to compete with an immobilized active-
site directed ligand.
Kinexus
Cells were treated with Triflorcas (3 mM) or vehicle for 72
hours. Protein extraction was performed as described by the
manufacturer (Kinexus Bioinformatics, Vancouver, Canada).
Samples were then analyzed by KINEXUS service using the
phospho-array KPSS-10.1.
FACS Analysis
Cells were treated with Triflorcas (3 mM), SU11274 (1 mM), or
vehicle for 48 hours. Cells were then fixed with 70% ethanol and
washed twice in PBS before treatment with RNase 100 mg/mL.
After staining with propidium iodide (50 mg/ml), cells were
analyzed by flow cytometry.
NCI60 Screening
Triflorcas was screened by the NCI towards a panel of 60 cell
lines. Cell sensitivity was assessed and results were expressed as
TGI (Total Growth Inhibition), GI50 (50% Growth Inhibition),
and LC50 (50% Lethal Concentration). Triflorcas action was
evaluated towards data from public resources including CellMiner
and COMPARE software. The COMPARE algorithm was used
to search for compounds tested on the NCI60 panel, to uncover
similar sensitivity profile to the Triflorcas. Luciferase constructs
(Cignal Reporters; QIAGEN) were used for reporter assay studies
and experiments were performed according to the manufacturers
instructions.
Bioinformatics Studies
To perform bioinformatics studies, we used three datasets
downloaded from the NCI data resources to identify potential
molecular signatures of NCI cancer cells sensitive to Triflorcas (last
update August 2010, http://dtp.nci.nih.gov/mtargets/download.
html). These databases included: ‘‘Microarrays’’, which contain
74,700 measured targets derived from large scale experiments
(Affymetrix U133 from Chiron, Affymetrix U95A from Novartis,
Affymetric HUM6000 from Millenium Pharmaceuticals, and
cDNA array data from Weinstein (NCI) and Brown & Botstein
(Stanford) groups); ‘‘all NCI dataset’’, which contains 12,845
measured targets derived from all small-scale measurements such
as protein, mRNA, miRNA, DNA methylation, mutations, SNPs,
enzyme activity, metabolites, but excluding Microarray; ‘‘only
Protein subset NCI’’, which contains 333 measured targets derived
from the NCI protein screening subset. The whole bioinformatics
analysis involved three steps. First, to compare data, we used the
developmental therapeutics program mean graph for the Tri-
florcas (five dose average data at GI50 endpoint) to extract the
sensitivity level of each cancer cell line tested. We then extracted
the expression level of signals scored in each NCI cancer cell line.
To allow comparison between Triflorcas cell sensitivity values and
molecular target expression values, each value was normalized
according to a standard normal distribution (standard score
defined as: mean= 0; standard deviation = 1). Second, we scored
the correlation existing between Triflorcas sensitivity values with
that of each molecular target value by using a statistical correlation
coefficient algorithm. The correlation coefficient spans values
between 21 and +1 and it permits to define five classes of
correlation: strong negative correlation (21 to 20.5), weak
negative correlation (20.5 to 0), weak positive correlation (0 to
0.5), strong positive correlation (0.5 to 1), and no correlation (0).
Only positive correlations (weak or strong) were included in these
studies in order to extrapolate mainly putative targets of Triflorcas.
Third, results were displayed in order to verify the strength of the
global (whole cell lines) or specific (individual cell line) correlation.
For this purpose, we defined a specific color code to highlight
differences and similarities between the sensitivity profile of
Triflorcas and changes in molecular targets. The color code was
assigned according to the standard score above described. All
values above 0 represent sensitivity of a given cell line to Triflorcas
and are indicated by green squares. All values below 0 stand for no
sensitivity and are represented by red squares. The same approach
was applied to encode the expression of a given molecular target in
each cell line: values above 0 were represented by green squares;
values below 0 were represented by red squares. As not all cell
lines screened for Triflorcas were included into the analysis of
some molecular targets, no available data were represented by
gray squares and were not taken into account for statistical
analysis. Finally, a web-based application was designed in order to:
1) automatically convert sensitivity of Triflorcas and changes in
molecular targets into a numeric format compliant; 2) score the
potential degree of correlation between cells response to Triflorcas
and the large set of molecular targets, using a statistical correlation
coefficient algorithm; 3) sort potential molecular targets according
to their correlation score; 4) display the result in a web browser to
retrieve a short list of molecular targets highlighting possible
molecular signatures.
Luciferase Reporter Assay
GTL-16 cells were transfected with luciferase reporter plasmids
that enable measuring the activity of p53, Smad2/3/4, AP-1 (as
read of the MAP2K2-JNK pathway) or NFAT (as readout of the
PKC-MARCKS pathway), and Elk1-SRF (as read of ERK
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signaling) promoters (Cignal Reporters, Qiagen). Transfection was
performed by using Lipofectamine according to the manufac-
turer’s protocol (Invitrogen). After 24 hours of transfection, cells
were treated or not with Triflorcas (3, 10, and 30 mM) for 48
hours, and then Luciferase activity was assessed. All Luciferase
assays were performed using a dual Luciferase assay kit according
to the manufacturer’s protocol (Promega).
Supporting Information
Figure S1 Triflorcas acts on cancer cells carrying
oncogenic Met, but not ErbB1. (A) Anchorage-independent
growth of H1437 cells was impaired in the presence of Triflorcas
(TFC), LY294002 (PI3K inhibitor), or A443654 (Akt inhibitor). (B)
Survival of GTL-16 cells was impaired in the presence of
LY294002 (PI3K inhibitor) or A443654 (Akt inhibitor). Values
are expressed as means6 s.e.m. **P,0.01; ***P,0.001; Student-t
test. (C) Reduced phosphorylation levels of Akt, but not ErbB1, by
Triflorcas was observed also in ErbB1-addicted BT474 cells. (D)
BT474 cells were treated with Triflorcas (TFC), SU11274, or
A443654 for 48 hours (mM), and viability was assessed with
CellTiterGlo (control: cntr).
(TIF)
Figure S2 Triflorcas interferes with tumor growth of
Met-addicted cancer cells in nude mice. Intra-peritoneal
injection of GTL-16 cells in nude mice leads to the development of
several nodules in the peritoneal cavity, offering the possibility to
evaluate compound efficacy on tumor weight and nodule
numbers. Triflorcas treatment (TFC; i.p. 30 mg.kg-1 every other
day) reduced nodule numbers. Reduction of nodule numbers was
of 82% for nodules smaller than 2 mm (vehicle: 8.664.6; TFC:
1.661.6; P=4.461025), 76% for nodules between 2 to 5 mm
(vehicle: 10.665.3; TFC: 2.661.8; P=5.261025), and 59% for
nodules bigger than 5 mm (vehicle: 2.361.6; TFC: 0.960.6;
P=9.961023). Values are reported as boxplots and expressed as
means 6 s.e.m. **P,0.001; Student-t test.
(TIF)
Figure S3 Triflorcas effects on the phosphorylation
status of molecules regulating cell cycle. Protein extracts
from GTL-16 cells were analyzed for the phosphorylation status of
different cell cycle proteins, using the Kinexus KPSS10.1 screen.
Intensities are represented as normalized counts per minute. Blue
and red lanes correspond to untreated or Triflorcas treated (3 mM)
cells, respectively.
(TIF)
Figure S4 Triflorcas effects on the NCI60 panel of
cancer cell lines. Triflorcas was applied to the NCI Anticancer
Drug Screen, at a single concentration of 10 mM. Mean growth
percentage is displayed. Mean graphs are constructed at each level
of effect, with bars depicting the deviation of individual tumor cell
line from the overall mean value for all the cells tested.
(TIF)
Figure S5 Cancer cell sensitivity to Triflorcas. Triflorcas
was assessed on the NCI60 panel of cancer cells at different doses,
ranging from 10 nM to 100 mM. Cell sensitivity is expressed as
GI50 (50% Growth Inhibition), TGI (Total Growth Inhibition),
and LC50 (50% Lethal Concentration).
(TIF)
Figure S6 Chemical formulas of Triflorcas, Phortress,
and other compounds characterized by the benzothia-
zole group.
(TIF)
Table S1 Ratios of gene expression analyzed with RT-
PCR stress and toxicity array. Cells were treated either with
SU11274 (SU) or with Triflorcas (TFC). NS indicate not
statistically significant changes.
(TIF)
Table S2 Selectivity profile of Triflorcas. Triflorcas was
screened against a KINOMEscan (http://www.kinomescan.com)
panel of 98 kinases. The ratio of binding (% TCF over control
condition) for each kinase is indicated. The arrows indicate the
kinases for which Triflorcas reduced more than 30% the binding
constant.
(TIF)
Table S3 Triflorcas effects on the phosphorylation
status of several cell cycle proteins analyzed by the
phospho-array KPSS 10.1 (Kinexus Bioinformatics).
GTL-16 cells were treated with vehicle (CTRL) or Triflorcas
(TFC; 3 mM) for 72 hours (first and second column, respectively).
Intensities are represented as normalized counts per minute
(CPM). Data for untreated or treated cells are reported. Changes
in phosphorylation levels are expressed as either percentage or
ratio of TFC-treated over control (third and fourth column,
respectively).
(TIF)
Table S4 Comparison of Triflorcas activity to standard
agents in the NCI60 screen using the COMPARE
software. The 10 drugs most similar in Triflorcas activity are
reported.
(TIF)
Table S5 Comparison of Triflorcas activity to synthetic
publicly available anticancer compounds in the NCI60
screen using the COMPARE software. The 9 drugs most
similar in activity are reported.
(TIF)
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